A. Blauvelt, “Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks’ Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies”, J of Skin, vol. 2, no. S1, p. S16, Feb. 2018.